Identification

Name
Fleroxacin
Accession Number
DB04576
Type
Small Molecule
Groups
Approved
Description

Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase.

Structure
Thumb
Synonyms
  • Fleroxacin
  • Fleroxacine
  • Fleroxacino
  • Fleroxacinum
  • Fleroxicin
  • FLRX
  • Megalocin
  • Megalocin (TN)
  • Megalone
  • Megalone (TN)
  • Megalosin
  • Quinodis
External IDs
RO 23-6240/000 / UNII-N804LDH51K
Categories
UNII
N804LDH51K
CAS number
79660-72-3
Weight
Average: 369.344
Monoisotopic: 369.130025941
Chemical Formula
C17H18F3N3O3
InChI Key
XBJBPGROQZJDOJ-UHFFFAOYSA-N
InChI
InChI=1S/C17H18F3N3O3/c1-21-4-6-22(7-5-21)15-12(19)8-10-14(13(15)20)23(3-2-18)9-11(16(10)24)17(25)26/h8-9H,2-7H2,1H3,(H,25,26)
IUPAC Name
6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
SMILES
CN1CCN(CC1)C1=C(F)C=C2C(=O)C(=CN(CCF)C2=C1F)C(O)=O

Pharmacology

Indication

Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone.

Structured Indications
Not Available
Pharmacodynamics

Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase.

Mechanism of action

The inhibition of DNA gyrase and DNA topoisomerase 2 leads ultimately to cell death as these enzymes are required for bacterial DNA replication, transcription, repair, strand supercoiling repair, and recombination.

TargetActionsOrganism
ADNA topoisomerase 2-alpha
inhibitor
Human
ADNA gyrase subunit A
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
ADNA topoisomerase 4 subunit A
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Absorption

Rapidly and well absorbed from the gastrointestinal tract after oral administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Fleroxacin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Fleroxacin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Fleroxacin.Experimental, Illicit
AcarboseFleroxacin may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AceclofenacAceclofenac may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
AcemetacinAcemetacin may increase the neuroexcitatory activities of Fleroxacin.Approved
AcenocoumarolFleroxacin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Fleroxacin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Fleroxacin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Fleroxacin.Approved, Vet Approved
AdapaleneAdapalene may increase the neuroexcitatory activities of Fleroxacin.Approved
AlbiglutideFleroxacin may increase the hypoglycemic activities of Albiglutide.Approved
AlclofenacAlclofenac may increase the neuroexcitatory activities of Fleroxacin.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Fleroxacin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Fleroxacin.Experimental, Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlminoprofenAlminoprofen may increase the neuroexcitatory activities of Fleroxacin.Experimental
AlogliptinFleroxacin may increase the hypoglycemic activities of Alogliptin.Approved
AloglutamolAloglutamol can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AluminiumAluminium can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Fleroxacin.Experimental, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Fleroxacin.Approved
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Fleroxacin.Approved
AndrographolideAndrographolide may increase the neuroexcitatory activities of Fleroxacin.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Fleroxacin.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Fleroxacin.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Fleroxacin.Investigational
AnisodamineAnisodamine may increase the neuroexcitatory activities of Fleroxacin.Investigational
AntipyrineAntipyrine may increase the neuroexcitatory activities of Fleroxacin.Approved
ApocyninApocynin may increase the neuroexcitatory activities of Fleroxacin.Investigational
ApremilastApremilast may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Fleroxacin.Investigational
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Fleroxacin.Withdrawn
AzelastineAzelastine may increase the neuroexcitatory activities of Fleroxacin.Approved
BalsalazideBalsalazide may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Fleroxacin.Approved, Investigational
BendazacBendazac may increase the neuroexcitatory activities of Fleroxacin.Experimental
BenorilateBenorilate may increase the neuroexcitatory activities of Fleroxacin.Experimental
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Fleroxacin.Withdrawn
BenzydamineBenzydamine may increase the neuroexcitatory activities of Fleroxacin.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Fleroxacin.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Fleroxacin.Approved, Investigational
BevoniumBevonium may increase the neuroexcitatory activities of Fleroxacin.Experimental
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BromfenacBromfenac may increase the neuroexcitatory activities of Fleroxacin.Approved
BromocriptineFleroxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BucillamineBucillamine may increase the neuroexcitatory activities of Fleroxacin.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Fleroxacin.Approved
BufexamacBufexamac may increase the neuroexcitatory activities of Fleroxacin.Experimental
BumadizoneBumadizone may increase the neuroexcitatory activities of Fleroxacin.Experimental
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fleroxacin.Approved
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CitrateCalcium Citrate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Calcium lactateCalcium lactate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateCalcium lactate gluconate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium laevulateCalcium laevulate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium pangamateCalcium pangamate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium PhosphateCalcium Phosphate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanagliflozinFleroxacin may increase the hypoglycemic activities of Canagliflozin.Approved
CarprofenCarprofen may increase the neuroexcitatory activities of Fleroxacin.Approved, Vet Approved, Withdrawn
CaseinCasein can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CastanospermineCastanospermine may increase the neuroexcitatory activities of Fleroxacin.Experimental
CelecoxibCelecoxib may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
ChloroquineChloroquine may increase the neuroexcitatory activities of Fleroxacin.Approved, Vet Approved
ChlorpropamideFleroxacin may increase the hypoglycemic activities of Chlorpropamide.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the neuroexcitatory activities of Fleroxacin.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Fleroxacin.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Fleroxacin.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Fleroxacin.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Fleroxacin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Fleroxacin.Approved
ClonixinClonixin may increase the neuroexcitatory activities of Fleroxacin.Approved
ClorindioneFleroxacin may increase the anticoagulant activities of Clorindione.Experimental
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Fleroxacin.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Fleroxacin.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Fleroxacin.Approved
CurcuminCurcumin may increase the neuroexcitatory activities of Fleroxacin.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Fleroxacin.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Fleroxacin.Experimental
D-LimoneneD-Limonene may increase the neuroexcitatory activities of Fleroxacin.Investigational
DapagliflozinFleroxacin may increase the hypoglycemic activities of Dapagliflozin.Approved
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Fleroxacin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Fleroxacin.Approved
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Fleroxacin.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Fleroxacin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Fleroxacin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Fleroxacin.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Fleroxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Fleroxacin.Vet Approved
DiclofenacDiclofenac may increase the neuroexcitatory activities of Fleroxacin.Approved, Vet Approved
DicoumarolFleroxacin may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Fleroxacin.Approved
DifenpiramideDifenpiramide may increase the neuroexcitatory activities of Fleroxacin.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Fleroxacin.Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Fleroxacin.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Fleroxacin.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Fleroxacin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Fleroxacin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Fleroxacin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Fleroxacin.Approved
DiphenadioneFleroxacin may increase the anticoagulant activities of Diphenadione.Experimental
DisopyramideFleroxacin may increase the hypoglycemic activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fleroxacin.Approved, Investigational
DroxicamDroxicam may increase the neuroexcitatory activities of Fleroxacin.Approved
DulaglutideFleroxacin may increase the hypoglycemic activities of Dulaglutide.Approved
DuvelisibDuvelisib may increase the neuroexcitatory activities of Fleroxacin.Investigational
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Fleroxacin.Approved
E-6201E-6201 may increase the neuroexcitatory activities of Fleroxacin.Investigational
EmpagliflozinFleroxacin may increase the hypoglycemic activities of Empagliflozin.Approved
EpirizoleEpirizole may increase the neuroexcitatory activities of Fleroxacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Fleroxacin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Fleroxacin.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Fleroxacin.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Fleroxacin.Approved
EtanerceptEtanercept may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
EthenzamideEthenzamide may increase the neuroexcitatory activities of Fleroxacin.Experimental
Ethyl biscoumacetateFleroxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
ExenatideFleroxacin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
exisulindexisulind may increase the neuroexcitatory activities of Fleroxacin.Investigational
FelbinacFelbinac may increase the neuroexcitatory activities of Fleroxacin.Experimental
FenbufenFenbufen may increase the neuroexcitatory activities of Fleroxacin.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Fleroxacin.Approved
FentiazacFentiazac may increase the neuroexcitatory activities of Fleroxacin.Experimental
FeprazoneFeprazone may increase the neuroexcitatory activities of Fleroxacin.Experimental
Ferric CarboxymaltoseThe serum concentration of Fleroxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric CitrateThe serum concentration of Fleroxacin can be decreased when it is combined with Ferric Citrate.Approved, Investigational
Ferric pyrophosphateThe serum concentration of Fleroxacin can be decreased when it is combined with Ferric pyrophosphate.Approved
Ferulic acidFerulic acid may increase the neuroexcitatory activities of Fleroxacin.Experimental
FloctafenineFloctafenine may increase the neuroexcitatory activities of Fleroxacin.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Fleroxacin.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Fleroxacin.Approved
FluindioneFleroxacin may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Fleroxacin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Fleroxacin.Approved, Investigational
FlunixinFlunixin may increase the neuroexcitatory activities of Fleroxacin.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the neuroexcitatory activities of Fleroxacin.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Fleroxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Fleroxacin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Fleroxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Fleroxacin.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Fleroxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Fleroxacin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Fleroxacin.Approved
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Fleroxacin.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Fleroxacin.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Fleroxacin.Approved, Investigational, Withdrawn
GitoformateGitoformate may decrease the cardiotoxic activities of Fleroxacin.Experimental
GliclazideFleroxacin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideFleroxacin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideFleroxacin may increase the hypoglycemic activities of Glipizide.Approved
GlyburideFleroxacin may increase the hypoglycemic activities of Glyburide.Approved
GuacetisalGuacetisal may increase the neuroexcitatory activities of Fleroxacin.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Fleroxacin.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Fleroxacin.Investigational
HigenamineHigenamine may increase the neuroexcitatory activities of Fleroxacin.Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fleroxacin.Approved, Vet Approved
HydrotalciteHydrotalcite can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
IbuprofenIbuprofen may increase the neuroexcitatory activities of Fleroxacin.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Fleroxacin.Withdrawn
IcatibantIcatibant may increase the neuroexcitatory activities of Fleroxacin.Approved
Imidazole salicylateImidazole salicylate may increase the neuroexcitatory activities of Fleroxacin.Experimental
IndobufenIndobufen may increase the neuroexcitatory activities of Fleroxacin.Investigational
IndomethacinIndomethacin may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Fleroxacin.Withdrawn
Insulin AspartFleroxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirFleroxacin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineFleroxacin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineFleroxacin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanFleroxacin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproFleroxacin may increase the hypoglycemic activities of Insulin Lispro.Approved
IronThe serum concentration of Fleroxacin can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Fleroxacin can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
Iron saccharateThe serum concentration of Fleroxacin can be decreased when it is combined with Iron saccharate.Approved
IsoxicamIsoxicam may increase the neuroexcitatory activities of Fleroxacin.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Fleroxacin.Investigational
KebuzoneKebuzone may increase the neuroexcitatory activities of Fleroxacin.Experimental
KetoprofenKetoprofen may increase the neuroexcitatory activities of Fleroxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Fleroxacin.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Fleroxacin.Experimental
Lanthanum carbonateThe serum concentration of Fleroxacin can be decreased when it is combined with Lanthanum carbonate.Approved
LeflunomideLeflunomide may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
LiraglutideFleroxacin may increase the hypoglycemic activities of Liraglutide.Approved
LisofyllineLisofylline may increase the neuroexcitatory activities of Fleroxacin.Investigational
LonazolacLonazolac may increase the neuroexcitatory activities of Fleroxacin.Experimental
LornoxicamLornoxicam may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Fleroxacin.Approved
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium salicylateThe serum concentration of Fleroxacin can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Magnesium SulfateThe serum concentration of Fleroxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MasoprocolMasoprocol may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Fleroxacin.Investigational
MecaserminFleroxacin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Fleroxacin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Fleroxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Fleroxacin.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Fleroxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Fleroxacin.Approved, Vet Approved
MesalazineMesalazine may increase the neuroexcitatory activities of Fleroxacin.Approved
MetamizoleMetamizole may increase the neuroexcitatory activities of Fleroxacin.Investigational, Withdrawn
MetforminFleroxacin may increase the hypoglycemic activities of Metformin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Fleroxacin.Approved, Vet Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Fleroxacin.Experimental
MifepristoneFleroxacin may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolFleroxacin may increase the hypoglycemic activities of Miglitol.Approved
MizoribineMizoribine may increase the neuroexcitatory activities of Fleroxacin.Investigational
MofebutazoneMofebutazone may increase the neuroexcitatory activities of Fleroxacin.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Fleroxacin.Approved, Vet Approved
Mycophenolate mofetilMycophenolate mofetil may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Fleroxacin.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Fleroxacin.Approved
NafamostatNafamostat may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
NaftifineNaftifine may increase the neuroexcitatory activities of Fleroxacin.Approved
NaproxenNaproxen may increase the neuroexcitatory activities of Fleroxacin.Approved, Vet Approved
NateglinideFleroxacin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Fleroxacin.Investigational
NepafenacNepafenac may increase the neuroexcitatory activities of Fleroxacin.Approved
NifenazoneNifenazone may increase the neuroexcitatory activities of Fleroxacin.Experimental
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Fleroxacin.Approved
NimesulideNimesulide may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Fleroxacin.Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Fleroxacin.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Fleroxacin.Investigational
OlopatadineOlopatadine may increase the neuroexcitatory activities of Fleroxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Fleroxacin.Approved
OrgoteinOrgotein may increase the neuroexcitatory activities of Fleroxacin.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Fleroxacin.Approved
OxaprozinOxaprozin may increase the neuroexcitatory activities of Fleroxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Fleroxacin.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fleroxacin.Approved, Vet Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Fleroxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Fleroxacin.Approved
ParthenolideParthenolide may increase the neuroexcitatory activities of Fleroxacin.Investigational
PentamidineFleroxacin may increase the hypoglycemic activities of Pentamidine.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Fleroxacin.Experimental
PhenindioneFleroxacin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonFleroxacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Fleroxacin.Approved, Vet Approved
PimecrolimusPimecrolimus may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
PioglitazoneFleroxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirfenidonePirfenidone may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
PiroxicamPiroxicam may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
PirprofenPirprofen may increase the neuroexcitatory activities of Fleroxacin.Experimental
PramlintideFleroxacin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PranoprofenPranoprofen may increase the neuroexcitatory activities of Fleroxacin.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Fleroxacin.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Fleroxacin.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Fleroxacin.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Fleroxacin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Fleroxacin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Fleroxacin.Experimental, Investigational
ProbenecidThe serum concentration of Fleroxacin can be increased when it is combined with Probenecid.Approved
ProglumetacinProglumetacin may increase the neuroexcitatory activities of Fleroxacin.Experimental
PropacetamolPropacetamol may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
PropyphenazonePropyphenazone may increase the neuroexcitatory activities of Fleroxacin.Experimental
ProquazoneProquazone may increase the neuroexcitatory activities of Fleroxacin.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Fleroxacin.Experimental
PTC299PTC299 may increase the neuroexcitatory activities of Fleroxacin.Investigational
QuinaprilThe serum concentration of Fleroxacin can be decreased when it is combined with Quinapril.Approved, Investigational
QuinineFleroxacin may increase the hypoglycemic activities of Quinine.Approved
RepaglinideFleroxacin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ResveratrolResveratrol may increase the neuroexcitatory activities of Fleroxacin.Approved, Experimental, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Fleroxacin.Approved
RofecoxibRofecoxib may increase the neuroexcitatory activities of Fleroxacin.Investigational, Withdrawn
RosiglitazoneFleroxacin may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SalicylamideSalicylamide may increase the neuroexcitatory activities of Fleroxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Fleroxacin.Approved, Vet Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Fleroxacin.Approved
SaxagliptinFleroxacin may increase the hypoglycemic activities of Saxagliptin.Approved
SemapimodSemapimod may increase the neuroexcitatory activities of Fleroxacin.Investigational
SeratrodastSeratrodast may increase the neuroexcitatory activities of Fleroxacin.Approved
SerrapeptaseSerrapeptase may increase the neuroexcitatory activities of Fleroxacin.Investigational
SevelamerSevelamer can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SitagliptinFleroxacin may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SRT501SRT501 may increase the neuroexcitatory activities of Fleroxacin.Investigational
Strontium ranelateThe serum concentration of Fleroxacin can be decreased when it is combined with Strontium ranelate.Approved
SucralfateThe serum concentration of Fleroxacin can be decreased when it is combined with Sucralfate.Approved
SulfadiazineFleroxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleFleroxacin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Fleroxacin.Approved
SulfisoxazoleFleroxacin may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the neuroexcitatory activities of Fleroxacin.Approved
SunitinibFleroxacin may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the neuroexcitatory activities of Fleroxacin.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the neuroexcitatory activities of Fleroxacin.Experimental
TarenflurbilTarenflurbil may increase the neuroexcitatory activities of Fleroxacin.Investigational
TenidapTenidap may increase the neuroexcitatory activities of Fleroxacin.Experimental
TenoxicamTenoxicam may increase the neuroexcitatory activities of Fleroxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Fleroxacin.Vet Approved
TeriflunomideTeriflunomide may increase the neuroexcitatory activities of Fleroxacin.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Fleroxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Fleroxacin.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Fleroxacin.Investigational
TioclomarolFleroxacin may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Fleroxacin.Approved
TolazamideFleroxacin may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideFleroxacin may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Fleroxacin.Approved
TolmetinTolmetin may increase the neuroexcitatory activities of Fleroxacin.Approved
TranilastTranilast may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Fleroxacin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Fleroxacin.Approved, Vet Approved
TribenosideTribenoside may increase the neuroexcitatory activities of Fleroxacin.Experimental
TriptolideTriptolide may increase the neuroexcitatory activities of Fleroxacin.Investigational
TromethamineTromethamine can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Fleroxacin.Approved
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Fleroxacin.Investigational, Withdrawn
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Fleroxacin.Approved, Investigational
WarfarinFleroxacin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
ZileutonZileuton may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the neuroexcitatory activities of Fleroxacin.Withdrawn
Food Interactions
  • Avoid excessive coffee or tea (caffeine)
  • Avoid milk, calcium containing dairy products, iron, magnesium, zinc, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.
  • Take with a full glass of water
  • Take without regard to meals

References

Synthesis Reference
US4398029
General References
Not Available
External Links
KEGG Drug
D01716
KEGG Compound
C13179
PubChem Compound
3357
PubChem Substance
46506357
ChemSpider
3240
ChEBI
31810
ChEMBL
CHEMBL6273
Therapeutic Targets Database
DAP000928
PharmGKB
PA164774762
Wikipedia
Fleroxacin
ATC Codes
J01MA08 — Fleroxacin

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)270 dec °CPhysProp
logP0.24ROSS,DL ET AL. (1992) (ION-CORRECT)
Caco2 permeability-4.81ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.284 mg/mLALOGPS
logP0.3ALOGPS
logP1.12ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)5.44ChemAxon
pKa (Strongest Basic)6.06ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area64.09 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity90.84 m3·mol-1ChemAxon
Polarizability34.71 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00di-0169000000-c300db33eb5021a5c529

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinoline carboxylic acids
Direct Parent
Quinoline carboxylic acids
Alternative Parents
N-arylpiperazines / Fluoroquinolones / Aminoquinolines and derivatives / Hydroquinolones / Haloquinolines / Hydroquinolines / Pyridinecarboxylic acids / Dialkylarylamines / N-methylpiperazines / Aryl fluorides
show 14 more
Substituents
Quinoline-3-carboxylic acid / Fluoroquinolone / N-arylpiperazine / Aminoquinoline / Haloquinoline / Dihydroquinolone / Dihydroquinoline / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives / Tertiary aliphatic/aromatic amine
show 32 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
quinolines, fluoroquinolone antibiotic (CHEBI:31810)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Ubiquitin binding
Specific Function
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segr...
Gene Name
TOP2A
Uniprot ID
P11388
Uniprot Name
DNA topoisomerase 2-alpha
Molecular Weight
174383.88 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Osheroff N: Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group. Antimicrob Agents Chemother. 1992 Apr;36(4):751-6. [PubMed:1323952]
  3. Hussy P, Maass G, Tummler B, Grosse F, Schomburg U: Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts. Antimicrob Agents Chemother. 1986 Jun;29(6):1073-8. [PubMed:3015015]
Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, inc...
Gene Name
gyrA
Uniprot ID
P43700
Uniprot Name
DNA gyrase subunit A
Molecular Weight
97817.145 Da
References
  1. Naber KG: Fleroxacin overview. Chemotherapy. 1996 Mar;42 Suppl 1:1-9. [PubMed:8861529]
  2. Asahina Y, Iwase K, Iinuma F, Hosaka M, Ishizaki T: Synthesis and antibacterial activity of 1-(2-fluorovinyl)-7-substituted-4-quinolone-3-carboxylic acid derivatives, conformationally restricted analogues of fleroxacin. J Med Chem. 2005 May 5;48(9):3194-202. [PubMed:15857125]
Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
Gene Name
parC
Uniprot ID
P43702
Uniprot Name
DNA topoisomerase 4 subunit A
Molecular Weight
83366.24 Da
References
  1. Drlica K, Zhao X: DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92. [PubMed:9293187]
  2. Chaudhry U, Ray K, Bala M, Saluja D: Mutation patterns in gyrA and parC genes of ciprofloxacin resistant isolates of Neisseria gonorrhoeae from India. Sex Transm Infect. 2002 Dec;78(6):440-4. [PubMed:12473806]
  3. Lee JK, Lee YS, Park YK, Kim BS: Mutations in the gyrA and parC genes in ciprofloxacin-resistant clinical isolates of Acinetobacter baumannii in Korea. Microbiol Immunol. 2005;49(7):647-53. [PubMed:16034208]
  4. Leavis HL, Willems RJ, Top J, Bonten MJ: High-level ciprofloxacin resistance from point mutations in gyrA and parC confined to global hospital-adapted clonal lineage CC17 of Enterococcus faecium. J Clin Microbiol. 2006 Mar;44(3):1059-64. [PubMed:16517894]

Drug created on September 11, 2007 09:20 / Updated on November 09, 2017 03:43